Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary
<p>Abstract</p> <p>Aim</p> <p>The objective of this observational study was to assess the status of glycemic control and associated patient-reported outcomes in ambulatory Hungarian patients with type 2 diabetes mellitus (T2DM) who were prescribed either a sulfonylurea...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2008-10-01
|
Series: | Health and Quality of Life Outcomes |
Online Access: | http://www.hqlo.com/content/6/1/88 |
id |
doaj-ebbedf2344f446298ae320920ed0feb4 |
---|---|
record_format |
Article |
spelling |
doaj-ebbedf2344f446298ae320920ed0feb42020-11-25T02:27:40ZengBMCHealth and Quality of Life Outcomes1477-75252008-10-01618810.1186/1477-7525-6-88Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in HungaryKarve SudeepPhatak HemantYin DonNagy LaszloErdesz DianaJermendy GyörgyEngel SamuelBalkrishnan Rajesh<p>Abstract</p> <p>Aim</p> <p>The objective of this observational study was to assess the status of glycemic control and associated patient-reported outcomes in ambulatory Hungarian patients with type 2 diabetes mellitus (T2DM) who were prescribed either a sulfonylurea (SU) or a thiazolidinedione (TZD) in addition to the prior metformin (MF) monotherapy.</p> <p>Methods</p> <p>Type 2 diabetics aged ≥ 30 years and who had added an SU or TZD to previous MF monotherapy at least 1 year prior to the visit date were identified during January 2006 to March 2007. Information on HbA1c (A1C), medication use and co-morbid conditions was extracted from the medical record up to 6 months prior to the addition of SU or TZD to MF (baseline), and a minimum of one year after the initiation of either SU or TZD. Glycemic control (A1C < 6.5%) was assessed using the last available A1C value in the medical record. Self-reported hypoglycemia, health-related quality of life (HRQoL) and treatment satisfaction were also assessed.</p> <p>Results</p> <p>A total of 414 patients (82% SU+MF and 18% TZD+MF) with a mean age of 60.5 years (SD = 9.4 years) participated in the study. About 27% of patients reported hypoglycemic episodes, with about one-third reporting episodes that resulted into interruption of activities or required medical/non-medical assistance. Three quarters of patients were not at glycemic goal and BMI was the only factor significantly associated with failure to have an A1C level < 6.5%. Patients' HRQoL was significantly associated with self-reported hypoglycemic episodes (p = 0.017), and duration of diabetes (p = 0.045).</p> <p>Conclusion</p> <p>Nearly 75% of patients were not at A1C goal of < 6.5% despite using two oral anti-hyperglycemic medications. Approximately 9% of patients reporting hypoglycemia required some kind of medical/non-medical assistance. Greater BMI at baseline was associated with an A1C level ≥ 6.5%. Finally, self- reports of hypoglycemia and duration of diabetes were associated with low HRQoL.</p> http://www.hqlo.com/content/6/1/88 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Karve Sudeep Phatak Hemant Yin Don Nagy Laszlo Erdesz Diana Jermendy György Engel Samuel Balkrishnan Rajesh |
spellingShingle |
Karve Sudeep Phatak Hemant Yin Don Nagy Laszlo Erdesz Diana Jermendy György Engel Samuel Balkrishnan Rajesh Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary Health and Quality of Life Outcomes |
author_facet |
Karve Sudeep Phatak Hemant Yin Don Nagy Laszlo Erdesz Diana Jermendy György Engel Samuel Balkrishnan Rajesh |
author_sort |
Karve Sudeep |
title |
Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary |
title_short |
Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary |
title_full |
Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary |
title_fullStr |
Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary |
title_full_unstemmed |
Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary |
title_sort |
outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in hungary |
publisher |
BMC |
series |
Health and Quality of Life Outcomes |
issn |
1477-7525 |
publishDate |
2008-10-01 |
description |
<p>Abstract</p> <p>Aim</p> <p>The objective of this observational study was to assess the status of glycemic control and associated patient-reported outcomes in ambulatory Hungarian patients with type 2 diabetes mellitus (T2DM) who were prescribed either a sulfonylurea (SU) or a thiazolidinedione (TZD) in addition to the prior metformin (MF) monotherapy.</p> <p>Methods</p> <p>Type 2 diabetics aged ≥ 30 years and who had added an SU or TZD to previous MF monotherapy at least 1 year prior to the visit date were identified during January 2006 to March 2007. Information on HbA1c (A1C), medication use and co-morbid conditions was extracted from the medical record up to 6 months prior to the addition of SU or TZD to MF (baseline), and a minimum of one year after the initiation of either SU or TZD. Glycemic control (A1C < 6.5%) was assessed using the last available A1C value in the medical record. Self-reported hypoglycemia, health-related quality of life (HRQoL) and treatment satisfaction were also assessed.</p> <p>Results</p> <p>A total of 414 patients (82% SU+MF and 18% TZD+MF) with a mean age of 60.5 years (SD = 9.4 years) participated in the study. About 27% of patients reported hypoglycemic episodes, with about one-third reporting episodes that resulted into interruption of activities or required medical/non-medical assistance. Three quarters of patients were not at glycemic goal and BMI was the only factor significantly associated with failure to have an A1C level < 6.5%. Patients' HRQoL was significantly associated with self-reported hypoglycemic episodes (p = 0.017), and duration of diabetes (p = 0.045).</p> <p>Conclusion</p> <p>Nearly 75% of patients were not at A1C goal of < 6.5% despite using two oral anti-hyperglycemic medications. Approximately 9% of patients reporting hypoglycemia required some kind of medical/non-medical assistance. Greater BMI at baseline was associated with an A1C level ≥ 6.5%. Finally, self- reports of hypoglycemia and duration of diabetes were associated with low HRQoL.</p> |
url |
http://www.hqlo.com/content/6/1/88 |
work_keys_str_mv |
AT karvesudeep outcomesofaddingsecondhypoglycemicdrugaftermetforminmonotherapyfailureamongtype2diabetesinhungary AT phatakhemant outcomesofaddingsecondhypoglycemicdrugaftermetforminmonotherapyfailureamongtype2diabetesinhungary AT yindon outcomesofaddingsecondhypoglycemicdrugaftermetforminmonotherapyfailureamongtype2diabetesinhungary AT nagylaszlo outcomesofaddingsecondhypoglycemicdrugaftermetforminmonotherapyfailureamongtype2diabetesinhungary AT erdeszdiana outcomesofaddingsecondhypoglycemicdrugaftermetforminmonotherapyfailureamongtype2diabetesinhungary AT jermendygyorgy outcomesofaddingsecondhypoglycemicdrugaftermetforminmonotherapyfailureamongtype2diabetesinhungary AT engelsamuel outcomesofaddingsecondhypoglycemicdrugaftermetforminmonotherapyfailureamongtype2diabetesinhungary AT balkrishnanrajesh outcomesofaddingsecondhypoglycemicdrugaftermetforminmonotherapyfailureamongtype2diabetesinhungary |
_version_ |
1724841489625776128 |